Improving Workflow
Meeting today's CT challenges

CT is growing in volume and represents a substantial portion of revenue for imaging centers and radiology departments.1 To control costs, maintain productivity, and preserve profitability, workflow efficiency is crucial.2

A 2012 study in the Journal of the American College of Radiology evaluated the effect syringe-less technology could have on enhancing this efficiency and contributing to overall operational improvements.2


 

The individuals who appear are for illustrative purposes only.
All persons depicted are models and not real patients.
IMPROVING WORKFLOW
PURPOSE
Meeting today's CT challenges
Comparing two technologies

The purpose of this study was to compare enhancement quality, performance efficiency, technologists’ satisfaction, and operation costs between 2 different power injectors in an outpatient setting–the syringe-less CT Exprès and a dual syringe system.2

IMPROVING WORKFLOW
METHODS
Meeting today's CT challenges
Selecting metrics that matter

In this prospective study, 275 consecutive outpatients (135 men, 140 women) scheduled for contrast enhanced CT were randomized and scanned using either of the 2 CT rooms, one with the syringe-less injector and one with the syringe-based injector. Techs had an average of 19 years experience and were randomized between the 2 rooms. Weight-based dosing protocols were used.2

The corresponding CECT studies were subjectively reviewed by 2 radiologists to rate the quality of contrast enhancement, and the injector systems were judged to have provided equivalent image quality.2

The 2 injector systems were then evaluated on the following criteria2:

  • Equipment preparation time (contrast media [CM], saline loading)
  • Releasing time (unloading of saline and CM)
  • Contrast media wastage incurred for each power injector
  • Technologists’ satisfaction – rated on a 10-point scale.
The individuals who appear are for illustrative purposes only.
All persons depicted are models and not real patients.
IMPROVING WORKFLOW
RESULTS
Meeting today's CT challenges
Take the tour
Breakthrough
technology
Improving
workflow
Demonstrated
safety

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE FOR ISOVUE®-300 (Iopamidol Injection 61%) Imaging Bulk Package and ISOVUE®-370 (Iopamidol Injection 76%) Imaging Bulk Package*
Isovue® (Iopamidol Injection) Imaging Bulk Package (IBP) is indicated for intravenous contrast enhancement of computed tomographic (CECT) imaging of the head and body in adult and pediatric patients.

IMPORTANT SAFETY INFORMATION

Isovue IS NOT FOR INTRATHECAL USE. Iopamidol Injection is available as Isovue-M® 
for intrathecal administration.

Caution must be exercised in patients with severely impaired renal function, those with combined renal and hepatic disease, or anuria, particularly when larger and repeat doses are administered. Radiopaque diagnostic contrast agents are potentially hazardous in patients with multiple myeloma or other paraproteinemia, particularly in those with therapeutically resistant anuria. Caution should be exercised in hydrating patients with underlying conditions that may be worsened by fluid overload, such as congestive heart failure. Diabetic nephropathy may predispose to acute renal impairment following intravascular contrast media administration. Acute renal impairment following contrast media administration may precipitate lactic acidosis in patients who are taking biguanides. Preparatory dehydration is dangerous and may contribute to acute renal failure in patients with advanced vascular disease, diabetic patients, and in susceptible nondiabetic patients (often elderly with preexisting renal disease). Patients should be well hydrated prior to and following iopamidol administration.

The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies).

*The Isovue Imaging Bulk Package is for use with an automated contrast injector or a contrast management system approved or cleared for use with it.

Please download full Prescribing Information by clicking here.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION
CT Exprès 3D Contrast Media Delivery System

INDICATIONS:
The CT Exprès 3D Contrast Media Delivery System is indicated for controlled automatic administration, on the venous side, of contrast media and saline, to human subjects while undergoing examination by means of a computed tomography (CT) scanner.

The CT Exprès 3D Contrast Media Delivery System is specifically indicated for use in CT procedures for the delivery of Isovue® (Iopamidol Injection) contrast media as supplied in an Imaging Bulk Package (IBP), for a maximum of 20 bottles of contrast media or a maximum of ten (10) hours, whichever comes first, per Day Set III HP disposable. The Bottle Spike disposable is for single-bottle use only and must be discarded with the contrast media bottle. The Patient Set must be discarded after each patient procedure.

The CT Exprès 3D is to be used only by and under quasi-continuous supervision of trained health care professionals in an appropriate licensed health care facility, in a room designated for radiological procedures that involve intravascular administration of a 
contrast agent.

CONTRAINDICATIONS
This device is not intended for injection of contrast media for coronary arteriography, or for any other use for which the device is not indicated.


Isovue and Isovue-M are registered trademarks of Bracco Diagnostics Inc.
CT Exprès is a trademark of Bracco Injeneering S.A.

Not all products are available in all countries. Please contact your Bracco representative.

Bracco Injeneering S.A. reserves the right at any time and without notice, to change the specifications and features described herein, or to change the production or adjust the product described.

Isovue and Isovue-M are currently manufactured for Bracco Diagnostics Inc. at two locations:
BIPSO GmbH, Singen (Germany) and Patheon Italia S.p.A., Ferentino (Italy).

CT Exprès is manufactured for Bracco Injeneering S.A., Avenue de Sévelin 46, CH-1004 Lausanne, Switzerland; imaging.bracco.com

CT Exprès is distributed by Bracco Diagnostic Inc.
259 Prospect Plains Road, Bldg. H
Monroe Township, NJ 08831 USA

Phone: (800) 631-5245; Fax: (609) 514-2424; Customer Service: 1-877-BRACCO 9 (1-877-272-2269)

©2016 Bracco Diagnostics Inc. All Rights Reserved.


TAKE THE TOUR
CT EXPRÈS
Dual Touch Screen:
Allows you to store and access more than 100 protocols with up to 8 phases per protocol.
Bottle Spikes:
Used to spike a single bottle of Isovue® (Iopamidol Injection) Imaging Bulk Package (IBP), which can remain spiked and installed on the injector for a maximum of 10 hours.
Day Set:
Can be used with a maximum of 20 bottles of Isovue® (Iopamidol Injection) Imaging Bulk Package, up to 4 liters, or for a total of 10 hours – whichever comes first.
Saline Spike:
Spikes a single bag of saline.
Saline Tag:
One tag to affix to each multi-dose saline bag on the injector.
Displays the “discard by” date and time (installation time + 10 hours).
Patient Set:
Single use component that supplies contrast/saline to patient via peristaltic pump technology.
Isovue® (Iopamidol Injection) Imaging Bulk Package (IBP) contrast bottles (200 or 500 mL)
EXPERIENCE THE
EXPRÈS LANE
First Name
Last Name
Email
Phone
Organization Name
Zip Code

Thank You for requesting to learn more about CT Exprés.

Your contact information has been sent to your appropriate Bracco representative and they will be contacting you soon.

Reference:

1.
IMV CT Market Outlook Report. November 2015. IMV Medical Information Division, Inc., 2015

Reference:

2.
Ma X, Singh A, Fay J, Boland G, Sahani DV. Comparison of dual-syringe and syringeless power injectors in outpatient MDCT practice: impact on the operator's performance, CT workflow, and operation cost. 
J Am Coll Radiol. 2012;9(8):578-582.